Highlights
1 patent
About
Immuno-oncology Drug Development
NeoTX is leveraging its proprietary Selective T cell Redirection (STR) platform to develop new targeted anticancer immunotherapies. STR binds a genetically engineered bacterial determinant to the tumor surface while simultaneously activating immune cells away from the suppressive tumor environment to mount an effective antibacterial response. The technology effectively converts a weak immune response against the tumor to a powerful yet safe native antibacterial immune reaction. The company's lead STR molecule, Naptumomab estafenatox, is currently in clinical development for advanced solid tumors.
Identity
| Name | NeoTX |
|---|---|
| Slug | neotx |
| Type / kind | startup |
| Crunchbase ID | predictive-therapeutics |
| Source _id | agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICA4KLAqZsKDA |
Status
| Status | active |
|---|---|
| Last update | 2026-05-17 |
Location
| HQ country code | IL |
|---|---|
| HQ region/district | Center District |
| HQ city | Rehovot |
| HQ address | Prof. Haim Pekeris Street 2, Rehovot, Israel |
Web & social
| Website | https://neotx.com/ |
|---|---|
| Careers page | https://neotx.com/careers |
| https://www.linkedin.com/company/27245756 | |
| Twitter / X | https://twitter.com/NeoTXThera |
Classifications
Primary sector Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsCells
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business models
B2B
Tags
drug-developmentdrug-discoverybiopharmaceuticalcancer-therapyoncologycancertherapeuticsimmunotherapycell-therapypharmaceuticals
Funding
| Total raised | $65.5M |
|---|---|
| Current stage | Series C |
Raw source document
Show full JSON (0 KB)
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}